Literature data suggest the hypothesis of a possible cross-talk between MAPK and RNF43 pathways in modulating the anti-tumor activity of BRAFV600E-targeted treatments, also related to the state of microsatellites (10). The gene discussed is RNF43; the disease is neoplasm.